Summary
Conditioning therapy with aggressive chemotherapy and irradiation induces a state of transient combined immunodeficiency in bonemarrow transplant recipients. This promotes the occurrence of severe cytomegalovirus (CMV) infections, the most frequent lethal complication after bone-marrow transplantation (BMT) at present.
Forty-four BMT recipients received CMV-IgG-hyperimmunoglobulin for CMV prophylaxis intravenously. The efficacy of this prophylaxis and possible risk factors for the occurrence of CMV-induced interstitial pneumonia (IP) were analyzed. Risk factors for the promotion of a CMV-IP were: additional immunosuppressive therapy after BMT, CMV-positive serostatus of the recipient, CMV-seropositive granulocyte transfusion, CMV infection immediately prior to BMT, and HLA-haploidentical BMT. In this study the incidence of graftversus-host disease was low and was not associated with the incidence of CMV infections. The use of T-cell-depleted grafts did not result in increased CMV infections or IP and may possibly have improved the immunological reconstitution.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- BMT:
-
Bone-marrow transplantation
- CMV:
-
Cytomegalovirus
- CMV-IG:
-
CMV-IgG-hyperimmunoglobulin
- GvHD:
-
Graft-versus-host disease
- IP:
-
Interstitial pneumonia
- IS:
-
Immunosuppressive therapy
References
Alpert G, Mazeron MC, Colimon R, Poltkin S (1985) Rapid detection of human cytomegalovirus in the urine of humans. J Infect Dis 152(3):631–633
Arnold R, Schmeiser T, Heit W, Frickhofen N, Pabst G, Heimpel H, Kubanek B (1986) Haemopoietic reconstitution after bone marrow transplantation. Exp Hematol 14:271–277
Barbara JAB, Tedder RS (1984) Viral infections transmitted by blood and its products. In: Prentice HG Infections in haematology, clinics in haematology. Saunders, London Philadelpia Toronto, vol 13, no 3, p 693
Blacklock HA, Griffiths P, Stirk P, Prentice HG (1985) Specific hyerimmune globulin for cytomegalovirus pneumonitis. Lancet:152–153
Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD (1986) Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314:1006–1010
Bunjes D, Heit W, Arnold R, Schmeiser T, Heimpel H (1985) Cyclosporin A as an alternative to cyclosphosphamide in the treatment of chronic GvHD. Transplantation 41(2):170–172
Collaborative DHPG treatment study group (1986) Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N. Engl J Med 314:801–805
Condie RM, O'Reilly RJ (1984) Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. Am J Med 76(3A):134–141
Drew WL, Miner RC (1982) Transfusion-related cytomegalovirus infection following noncardiac surgery. JAMA 17:2389
Funada H, Harada M, Yoshida T, Hattori KI (1984) Interstitial pneumonia after allogeneic and autologus bone marrow transplantation. Jpn J Clin Oncol 14 [Suppl 1]:519–530
Gaya H (1984) Rational basis for the choice of regimens for empirical therapy of sepsis in granulocytopenic patients. In: Prentice HG (ed) Infections in haematology, clinics in haematology. Saunders, London Philadelphia Toronto; vol 13, no 3, pp 573–586
Gratama JW, Middeldorp JM, Sinnige LGF, Van der Meer JWM, D'Armaro J, Jansen J, Zwaan FE, Brand A, De Gast GC, The TH (1985) Cytomegalovirus immunity in allogeneic marrow grafting. Transplantation 40(5):510–514
Heit W, Bunjes D, Wiesneth M, Schmeiser T, Arnold R, Hale G, Waldman H, Heimpel H (1986) Ex vivo T-cell depletion with the monoclonal antibody Campath 1 plus human complement effectively prevents acute GvHD in allogeneic bone marrow transplantation. Br J Haematol 64:479–486
Hersman J, Meyers JD, Thomas ED, Buckner CD, Clift R (1982) The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Am Int Med 96:149–152
Heymer B, Krüger G, Arnold R, Schmeiser T, Friedrich W, Kubanek B, Heimpel H (1984) GvH-reaction and morphology of bone marrow after allogeneic bone marrow transplantation. In: Lennert, Kast (ed) Pathology of bone marrow. Gustav-Fischer-Verlag
Jordan MC, Jordan GW, Stevens JO, Miller G (1984) Latent herpesviruses of humans. Ann Intern Med 100(6):866–880
Kubanek B, Ernst P, Ostendorf P, Schäfer U, Wolf H (1985) Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients. Transplantation Proc 17(1):468–469
Landry ML, Mayo DR, Hsiung GD (1983) The need for a rapid and accurate viral diagnosis. Pharmac Ther 18:107–132
Ljungman P, Lönnquist B, Wahren B, Ringdén O, Gahrton G (1985) Lymphocyte responses after cytomegalovirus infection in bone marrow transplant recipients — a one-year follow-up. Transplantation 40(5):515–520
Meyers JD (1984) Cytomegalovirus infection following marrow transplantation: risk, treatment and prevention. Birth Defects 20(1):101–117
Meyers JD, Atkinson K (1983) Infection in bone marrow transplantation. In: Nathan DG (ed) Bone marrow transplantation, clinics in haematology. Saunders, London Philadelphia Toronto, vol 12, no 3, pp 791–811
Meyers JD, Flourney N, Thomas ED (1980) Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis 142(6):816–824
Meyers JD, McGuffin RW, Neiman PE, Singer JW, Thomas ED (1980) Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J Inf Dis 141:555–562
Meyers JD, Leszcyznski J, Zaia JA, Flournoy N, Newton B, Snydman DR, Wright GG, Levin MJ, Thomas ED (1983) Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Int Med 98:442–446
Onorato IM, Morens DM, Martone WJ, Stansfield SK (1985) Epidemiology of cytomegaloviral infections: recommendations for prevention and control. Rev Infect Dis 7(4):479–497
Osborn JE (1981) Cytomegalovirus: pathogenicity, immunity, and vaccine initiatives. J Infect Dis 143(4):618–630
O'Reilly RJ, Reich L, Gold J, Kirkpatrick D, Dinsmore R, Kapoor N, Condie R (1983) A randomized trial of intravenous hyperimmune-globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation: preliminary results. Transpl Proc 15:1405–1411
Osterwalder B, Reusser P, Gratwohl A, Gratama JW, The Th, Speck B (1985) Importance of highly sensitive serological tests for cytomegalovirus in bone marrow transplant patients. Lancet II:442
Panjwani DD, Ball MG, Berry NJ, Wimperis JZ, Blackloch HA, Prentice HG, Hoffbrand AV, Griffiths PD (1985) Virological and serological diagnosis of cytomegalovirus infection in bone marrow allograft recipients. J Med Virol 16:357–365
Peterson KP, McGlave P, Ramsay NKC, Rhame F, Cohen E, Perry GS, Goldman AI, Kersey J (1983) A prospective study of infectious diseases following bone marrow transplantation: emergence of aspergillus and cytomegalovirus as the major causes of mortality. Infect Control 4(2):81–89
Quinnan GV, Rook AH (1984) The importance of cytotoxic cellular immunity in the protection from cytomegalovirus infection. Birth Defects 20(1):245–261
Rook AH, Quinnan GV, Frederick WJR, Manischewitz JF, Kirmani N, Dantzler T, Lee BB, Currier CB (1984) Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. Am J Med 76:385–392
Saral R, Burus WH, Prentice HG (1984) Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patients. In: Prentice HG (ed) Infections haematology, clinics in haematology. Saunders, London Philadelphia Toronto, vol 13, no 3, pp 645–660
Schmeiser Th, Heit W (1985) Risk factors for cytomegalovirus (CMV)-pneumonitis in bone marrow transplantation (BMT)-recipients receiving CMV-hyperimmunoglobulin as prophylaxis. Immun Infekt 13(6):302–306
Schmeiser T, Kurrle E, Arnold R, Heit W, Krieger D, Kubanek B, Heimpel H, (1984) Application of antimicrobial prophylactic treatment for prevention of infection and graft-versus-host-disease in allogeneic bone marrow transplantation. Exp Hematol 12 [Suppl 15]:105–106
Schmeiser Th, Arnold R, Wiesneth M, Bunjes D, Heimpel H, Heit W (1986) CMV-IgG-hyperimmunoglobulin for the prevention of CMV-infection in BMT-recipients. Bone Marrow Transplantation:64
Schmeiser T, Kurrle E, Arnold R, Wiesneth M, Bunjes D, Heimpel H, Heit W (1986) The influence of T-cell depletion on the occurrence of infections after bone marrow transplantation. Blut 53(3):199–200
Skinhoj P, Anderson HK, Moller J, Jacobsen N (1984) Cytomegalovirus infection after bone marrow transplantation: relation of pneumonia to postgrafting immunosuppressive treatment. J Med Virol 14:91–99
Verdonk LF, De Gast G (1984) Is cytomegalovirus infection a major cause of T cell alterations after (autologous) bone-marrow transplantation? Lancet:932
Vilmer E, Mazeron MC, Rabian C et al. (1985) Clinical significance of cytomegalovirus viremia in bone marrow transplantation. Transplantation 40:30–35
Wade JC, Hintz M, McGuffin RW, Springmeyer SC, Connor JD, Meyers JD (1982) Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med [Acyclovir Symp 1A] 73:249–256
Wade JC, McGuffin RW, Springmeyer SC, Newton B, Singer JW, Meyers JD (1983) Treatment of cytomegalovirus pneumonia with high-dose acyclovir and human leukocyte interferon. J Inf Dis 148:557–562
Wahren B, Linde A, Sundqvist V, Ljungman P, Lönnqvist B, Ringden O (1984) IgG-subclass-specific CMV reactivity in bone marrow transplant recipients. Transplantation 38(5):479–483
Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HEM, Kolb HJ, Hartz AJ, Rimm AA (1986) Interstitial pneumonitis after bone marrow transplantation assessment of risk factors. Ann Int Med 104:168–175
Winston DJ, Ho WG, Howell CL, Miller MJ, Mickey R, Martin WJ, Lin C, Gale RP (1980) Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med 93:671–675
Winston DJ, Pollard RB, Ho WG, Gallagher JG, Rasmussen LE, Huang SN, Lin C, Gossett TG, Merigan TC, Gale RP (1982) Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Int Med 97:11–18
Winston DJ, Ho WG, Lin CH, Budinger MD, Champlin RE, Gale RP (1984) Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial. Am J Med 76(3A):128–133
Winston DJ, Huang E, Miller MJ, Lin C, Ho WG, Gale RP, Champlin RE (1985) Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Ann Int Med 102:16–20
Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE (1987) Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Int Med 106:12–18
Wong KK, Hirsch MS (1984) Herpes virus infections in patients with neoplastic disease, diagnosis and therapy. Am J Med 76:464–478
Zaia JA, Forman SJ, Gallagher MT, Vanderwal-Urbina E, Blume KG (1984) Prolonged human cytomegalovirus viremia following bone marrow transplantation. Transplantation 37(3):315–317
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmeiser, T., Heit, W., Arnold, R. et al. Cytomegalovirus (CMV) infections in patients receiving CMV-IgG-hyperimmunoglobulin prophylaxis after bone-marrow transplantation. Klin Wochenschr 65, 967–974 (1987). https://doi.org/10.1007/BF01717831
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01717831